[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-457473-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-457473-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","hypoxia-promotes-bcma-loss-and-a-suppressive-secretome-thereby-hindering-cart-cell-therapy-in-multiple-myeloma","Hypoxia promotes BCMA loss and a suppressive secretome thereby hindering CART cell therapy in multiple myeloma","","Hypoxia in the bone marrow microenvironment reshapes multiple myeloma biology and immune interactions, yet its impact on immunotherapy-relevant antigen levels and the tumor secretome is insufficiently defined. Using normoxic (21% O2) versus hypoxic (1% O2) culture conditions, the study evaluates BCMA expression, anti-BCMA CAR T cell cytotoxicity, cytokine release, and the role of conditioned media and small extracellular vesicles, supported by RNA profiling.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/hypoxia-promotes-bcma-loss-and-a-suppressive-secretome-thereby-hindering-cart-cell-therapy-in-multiple-myeloma/457473/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/hypoxia-promotes-bcma-loss-and-a-suppressive-secretome-thereby-hindering-cart-cell-therapy-in-multiple-myeloma/457473.png","ImageObject",300,407,{"name":42,"@type":43},"Elsa","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-30",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How does hypoxia affect BCMA expression in multiple myeloma cells?","Question",{"text":63,"@type":64},"Hypoxic culture reduces BCMA surface and total protein expression compared with normoxia, which decreases CAR-mediated signaling.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What is the effect of the hypoxic tumor secretome on CAR T cell therapy?",{"text":68,"@type":64},"The hypoxic secretome further lowers BCMA levels and significantly impairs CAR T cell killing and cytokine production, partially reversible by γ-secretase inhibition.",{"name":70,"@type":61,"acceptedAnswer":71},"What role do small extracellular vesicles (sEVs) play under hypoxia?",{"text":72,"@type":64},"Hypoxia increases sEV release, and RNA profiling reveals a hypoxia-induced RNA signature with potential immunomodulatory roles.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},457473,1791183933,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":55,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},137455077381,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Tu etal. Experimental Hematology & Oncology (2026) 15:1 [https://doi.org/10.1186/s40164-025-00732-6](https://doi.org/10.1186/s40164-025-00732-6)  \nExperimental Hematology & Oncology  \nCORRESPONDENCE Open Access  \nHypoxia promotes BCMA loss and a   \nsuppressive secretome thereby hindering CART cell therapy in multiple myeloma  \nChenggong Tu 1†, ArneVan der Vreken 1†, Fien Meeus 1, Lauren van den Broecke 1, Jack Brons 1, Kim DeVeirman 1, Karin Vanderkerken 1, Elke De Bruyne 1, Karine Breckpot 1 and El ine Menu 1*  \nAbstract  \nIntroduction Multiple myeloma (MM) develops in the hypoxic bone marrow (BM) microenvironment, which alters tumor behavior and immune responses. While hypoxia is known to directly suppress immune function, its effect on immunotherapy-relevant antigen expression and the MM secretome remains underexplored. Here, we investigated how hypoxia affects BCMA expression and BCMA-targeted CART cell responses.  \nMethods MM cells were cultured under normoxia (21% O₂) or hypoxia (1% O₂) . BCMA surface and total expression were analyzed. Anti-BCMA CART cells were co-cultured with normoxic or hypoxic MM cells to assess cytotoxicity and cytokine release. Conditioned media and small extracellular vesicles (sEVs) were isolated, quantified, and RNA-profiled. Results MM cells cultured in hypoxia showed reduced BCMA surface and total protein expression, resulting in reduced CAR-mediated signaling. Importantly, the hypoxic tumor secretome further reduced BCMA levels and significantly impaired CART cell killing and cytokine production, which was partially reversible by γ-secretase inhibition. To dissect the suppressive nature of the hypoxic secretome, we identified an increase in small extracellular vesicle (sEV) release under hypoxia. RNA profiling of sEVs revealed a hypoxia-induced RNA signature with potential immunomodulatory roles.  \nConclusion This study shows that hypoxia diminishes BCMA expression and enhances secretion of immunosuppressive factors, including sEVs, thereby limiting the efficacy of BCMA CART cell therapy in MM.  \n†Chenggong Tu and Arne Van der Vreken are shared first-authorship.  \n*Correspondence: Eline Menu [Eline.Menu@vub.be](Eline.Menu@vub.be)  \n1Department of Biomedical Sciences, Translational Oncology Research Center, Vrije Universiteit Brussel, Brussels, Belgium  \nTo the Editor,  \nMultiple myeloma (MM) is a hematological malignancy characterized by the uncontrolled proliferation of plasma cells in the bone marrow (BM) [1]. The BM microenvironment is inherently hypoxic, with localized hypoxic niches that contribute to disease progression, metabolic reprogramming, and resistance to therapies such as proteasome inhibitors [1–3]. Recent therapeutic advances in MM have focused on immunotherapies, including mRNA vaccines, T-cell engagers (TCEs), monoclonal antibodies, and chimeric antigen receptor (CAR) T cell therapy [4, 5], particularly those targeting B  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/l](vecommons.org/l)icenses/by-n","cbCaiekV2XyvyVAO","https://ap.wps.com/l/cbCaiekV2XyvyVAO","pdf",1297041,"English","# Abstract\n# Introduction\n# Methods\n# Results\n# Conclusion\n# Figures","[{\"question\":\"How does hypoxia affect BCMA expression in multiple myeloma cells?\",\"answer\":\"Hypoxic culture reduces BCMA surface and total protein expression compared with normoxia, which decreases CAR-mediated signaling.\"},{\"question\":\"What is the effect of the hypoxic tumor secretome on CAR T cell therapy?\",\"answer\":\"The hypoxic secretome further lowers BCMA levels and significantly impairs CAR T cell killing and cytokine production, partially reversible by γ-secretase inhibition.\"},{\"question\":\"What role do small extracellular vesicles (sEVs) play under hypoxia?\",\"answer\":\"Hypoxia increases sEV release, and RNA profiling reveals a hypoxia-induced RNA signature with potential immunomodulatory roles.\"}]","Hypoxia promotes BCMA loss and a suppressive secretome thereby hindering CART cell therapy in multiple myeloma | PDF",1790749439,15,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/154a9d9adcd970ce4dd07171ae691326.webp",983,1310,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/15f1dc21ebb3d458b068caa6a462a3c1.webp",982,1309,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/9f92a80afe39747d81114bb85e357acd.webp",981,1308,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/ad44fdfb3fc419bc9ac1c7c01ca18359.webp",980,1306]